Donna S. Cox

3.3k total citations · 1 hit paper
55 papers, 2.4k citations indexed

About

Donna S. Cox is a scholar working on Molecular Biology, Oncology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Donna S. Cox has authored 55 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 16 papers in Oncology and 8 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Donna S. Cox's work include Melanoma and MAPK Pathways (12 papers), PI3K/AKT/mTOR signaling in cancer (10 papers) and Heparin-Induced Thrombocytopenia and Thrombosis (6 papers). Donna S. Cox is often cited by papers focused on Melanoma and MAPK Pathways (12 papers), PI3K/AKT/mTOR signaling in cancer (10 papers) and Heparin-Induced Thrombocytopenia and Thrombosis (6 papers). Donna S. Cox collaborates with scholars based in United States, United Kingdom and India. Donna S. Cox's co-authors include Natalie D. Eddington, Howard A. Burris, Kenneth R. Scott, Thomas J. Balkin, Ronald Otterstetter, Gary H. Kamimori, Gregory Belenky, Chetan S. Karyekar, Jeffrey R. Infante and Douglas J. DeMarini and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Neurology.

In The Last Decade

Donna S. Cox

53 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

2012 424 citations Jeffrey R. Infante, Michael S. Gordon et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Donna S. Cox United States	26	881	739	280	240	237	55	2.4k
George L. Dale United States	37	890 1.0×	361 0.5×	150 0.5×	723 3.0×	331 1.4×	113	4.3k
John F. Boylan United States	31	1.3k 1.4×	599 0.8×	260 0.9×	671 2.8×	911 3.8×	60	3.6k
Andreas H. Wagner Germany	29	766 0.9×	260 0.4×	78 0.3×	244 1.0×	662 2.8×	97	2.9k
Manish Tandon United States	26	669 0.8×	336 0.5×	106 0.4×	180 0.8×	423 1.8×	96	2.0k
Lili Fu China	25	1.5k 1.7×	158 0.2×	163 0.6×	275 1.1×	390 1.6×	86	3.2k
Yan Cheng China	32	1.6k 1.8×	437 0.6×	75 0.3×	508 2.1×	177 0.7×	104	3.2k
Yoshihiko Ikeda Japan	28	675 0.8×	258 0.3×	347 1.2×	272 1.1×	528 2.2×	157	3.0k
Xin Liang China	33	1.7k 1.9×	505 0.7×	130 0.5×	342 1.4×	241 1.0×	104	3.1k
Hans‐Georg Eichler Austria	33	798 0.9×	361 0.5×	34 0.1×	260 1.1×	347 1.5×	82	3.6k
Takeo Tanaka Japan	25	611 0.7×	196 0.3×	81 0.3×	221 0.9×	253 1.1×	82	1.6k

Countries citing papers authored by Donna S. Cox

Since Specialization

Citations

This map shows the geographic impact of Donna S. Cox's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donna S. Cox with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donna S. Cox more than expected).

Fields of papers citing papers by Donna S. Cox

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donna S. Cox. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donna S. Cox. The network helps show where Donna S. Cox may publish in the future.

Co-authorship network of co-authors of Donna S. Cox

This figure shows the co-authorship network connecting the top 25 collaborators of Donna S. Cox. A scholar is included among the top collaborators of Donna S. Cox based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donna S. Cox. Donna S. Cox is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cox, Donna S., Ravi Shankar Prasad Singh, Phylinda L. S. Chan, et al.. (2024). A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir. Clinical Pharmacokinetics. 63(1). 27–42. 21 indexed citations

Wan, Katty, Bharat Damle, Haihong Shi, et al.. (2023). Patient Centric Microsampling to Support Paxlovid Clinical Development: Bridging and Implementation. Clinical Pharmacology & Therapeutics. 115(1). 42–51. 11 indexed citations

Chan, Phylinda L. S., Ravi Shankar Prasad Singh, Donna S. Cox, et al.. (2023). Dosing recommendation of nirmatrelvir/ritonavir using an integrated population pharmacokinetic analysis. CPT Pharmacometrics & Systems Pharmacology. 12(12). 1897–1910. 5 indexed citations

Cox, Donna S., et al.. (2021). Randomized, Open‐Label, Single‐Dose, Parallel‐Group Pharmacokinetic Study of PF‐06410293 (adalimumab‐afzb), an Adalimumab Biosimilar, by Subcutaneous Dosing Using a Prefilled Syringe or a Prefilled Pen in Healthy Subjects. Clinical Pharmacology in Drug Development. 10(10). 1166–1173. 3 indexed citations

Cox, Donna S., et al.. (2018). Cardiovascular Safety Assessment of Deutetrabenazine in Healthy Volunteers and Implications for Patients With Huntington Disease or Tardive Dyskinesia (P4.080). Neurology. 90(15_supplement).

Cox, Donna S., et al.. (2018). 127 Cardiovascular Safety Assessment of Deutetrabenazine in Healthy Volunteers and Implications for Patients With Huntington Disease or Tardive Dyskinesia. CNS Spectrums. 23(1). 80–80. 1 indexed citations

Yau, Thomas, Riccardo Lencioni, Wattana Sukeepaisarnjaroen, et al.. (2016). A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research. 23(10). 2405–2413. 58 indexed citations

Ouellet, Danièle, Nastya Kassir, Samer Mouksassi, et al.. (2016). Population pharmacokinetics and exposure–response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma. Cancer Chemotherapy and Pharmacology. 77(4). 807–817. 42 indexed citations

Patnaik, Amita, Anthony W. Tolcher, Kyriakos P. Papadopoulos, et al.. (2016). Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours. Cancer Chemotherapy and Pharmacology. 78(3). 491–500. 4 indexed citations

10.

Tolcher, Anthony W., Johanna C. Bendell, Kyriakos P. Papadopoulos, et al.. (2014). A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. Annals of Oncology. 26(1). 58–64. 100 indexed citations

11.

Cox, Donna S., Alicia J. Allred, Yanyan Zhou, et al.. (2014). Relative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumors. Clinical Pharmacology in Drug Development. 4(4). 287–294. 10 indexed citations

12.

Infante, Jeffrey R., Kyriakos P. Papadopoulos, Johanna C. Bendell, et al.. (2013). A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. European Journal of Cancer. 49(9). 2077–2085. 64 indexed citations

13.

Kurzrock, Razelle, Akash Patnaik, Sidney W. Fu, et al.. (2011). Phase I dose-escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795).. Journal of Clinical Oncology. 29(15_suppl). 3085–3085. 26 indexed citations

14.

Grudell, April, Michael Camilleri, Kimberly L. Jensen, et al.. (2008). Dose-response effect of a β₃-adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health. American Journal of Physiology-Gastrointestinal and Liver Physiology. 294(5). G1114–G1119. 27 indexed citations

15.

Eddington, Natalie D., Donna S. Cox, Ralph R. Roberts, et al.. (2002). Synthesis and anticonvulsant activity of enaminones.. European Journal of Medicinal Chemistry. 37(8). 635–648. 83 indexed citations

16.

Kamimori, Gary H., Chetan S. Karyekar, Ronald Otterstetter, et al.. (2002). The rate of absorption and relative bioavailability of caffeine administered in chewing gum versus capsules to normal healthy volunteers. International Journal of Pharmaceutics. 234(1-2). 159–167. 273 indexed citations

17.

Cox, Donna S., et al.. (2001). Influence of Multidrug Resistance (MDR) Proteins at the Blood–Brain Barrier on the Transport and Brain Distribution of Enaminone Anticonvulsants. Journal of Pharmaceutical Sciences. 90(10). 1540–1552. 42 indexed citations

18.

Cox, Donna S., et al.. (2000). Analysis of Glucosamine and Chondroitin Sulfate Content in Marketed Products and the Caco-2 Permeability of Chondroitin Sulfate Raw Materials. 69 indexed citations

19.

Eddington, Natalie D., et al.. (2000). Enaminones-Versatile Therapeutic Pharmacophores. Further Advances. Current Medicinal Chemistry. 7(4). 417–436. 107 indexed citations

20.

Burstein, Aaron H., Donna S. Cox, Bipin Mistry, & Natalie D. Eddington. (1999). Phenytoin pharmacokinetics following oral administration of phenytoin suspension and fosphenytoin solution to rats. Epilepsy Research. 34(2-3). 129–133. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact